/content/dam/www/people-profile-photos/j/holly-janes/holly-janes-d.jpg
Janes
Holly Janes, PhD

Holly Janes, PhD

  • Professor and Program Head, Biostatistics, Bioinformatics and Epidemiology Program, Vaccine and Infectious Disease Division, Fred Hutch
  • Professor, Biostatistics Program, Public Health Sciences Division, Fred Hutch
  • Member, Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch
  • Affiliate Professor, Biostatistics, University of Washington
  • Graduate Faculty, Biostatistics, University of Washington
206.667.6353
206.667.4378

Background

Dr. Holly Janes is a biostatistician working on the design and analysis of vaccine studies, with a particular expertise in HIV prevention and vaccine science. She also develops and applies statistical methodology for evaluating biomarkers for risk prediction and optimizing treatment decisions

Education

PhD, Biostatistics, University of Washington, 2005

MS, Mathematics, University of Massachusetts, 2000

BA, Philosophy of Physical Science and Mathematical Modeling, Skidmore College, 1998

Research Interests

Statistical design and analysis of vaccine efficacy trials

HIV vaccine development

Clinical trial design

Statistical methods for biomarker evaluation

Pediatric vaccine trials

Current Projects

Leadership for the Statistical Data Management Center of the HIV Vaccine Trials Network

Statistical methods for HIV prevention efficacy trials

Statistical methods for human challenge studies

Statistical evaluation of biomarkers for making treatment decisions

Find a Clinical Trial Led by Dr. Janes

Stories

All news
The benefits of HIV research? Let us count the ways HIV work has helped shape the FDA, provided drugs for other infections, changed health systems globally and more, say Fred Hutch experts November 28, 2025
Starting the year smarter How patients, providers, researchers and others stay informed amid a deluge of data and information January 8, 2025
Latest Fred Hutch research on COVID-19 How Hutch scientists have been tackling coronavirus in lab and clinic June 30, 2022